App-Quantinova.ai

Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trialA feasibility analysis.

Jeeyun Lee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Monitoring anti-PD-1 therapy efficacy by circulating tumor DNA: a prospective cohort.

Francesca Riva - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

Performance of standardized BEAMing platform for detecting RAS mutations in the blood of metastatic colorectal cancer (mCRC) patients.

Frederick S. Jones - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Early, molecular detection of cancer utilizing circulating cell-free DNA assay with ultra high accuracy and sensitivity.

Stefanie Mortimer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Functional characterization of VUS mutations found in patients cell-free circulating tumor DNA (ctDNA) using Precision Cancer Analysis System (PCAS).

Gabi Tarcic - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Solid malignancies

N/A

Circulating tumor DNA before and after surgical resection in patients with peritoneal carcinomatosis.

Joel Micah Baumgartner - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peritoneal carcinomatosis

N/A

Quantitative urinary KRAS for treatment decisions in patients with metastatic colorectal cancer (mCRC).

Vladislava Melnikova - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Serial circulating tumor DNA (ctDNA) and recurrence risk in patients (pts) with resectable colorectal liver metastasis (CLM).

Jeanne Tie - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal liver metastases

N/A

Non-invasive detection of crizotinib resistance in ALK-rearranged lung adenocarcinoma directs treatment with next-generation ALK inhibitors.

Nnamdi Ihuegbu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Crizotinib

Simultaneous EGFR mutation detection and copy number assessment in circulating tumour DNA (ctDNA) to inform molecular methods of therapy resistance and plasma ctDNA content in lung adenocarcinoma.

Alexandra Pender - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Comparison of plasma ctDNA from the portal and peripheral veins of resectable CRC patients.

Xin-Xing Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC).

Ricardo Lima Barros Costa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Comparative analysis of the representative value of somatic mutation profiles derived from ctDNA and other updated lung tumor biopsy alternative in non-resectable non-small cell lung cancer patients.

Xiaozheng Kang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer.

Christine A. Parkinson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High grade serous ovarian cancer

TP53

Clinical utility of circulating tumor DNA (ctDNA) in resectable pancreatic ductal adenocarcinoma (PDAC).

Hui-Li Wong - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

TP53

Practical applications of liquid biopsy in the colorectal cancer treatment.

Koichi Suzuki - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Mutation detection in circulating tumor DNA in stage I vs. later stage cancer samples.

Aaron Chen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors.

Phil Stephens - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Mutation detection in cell free DNA from healthy donors.

Anja Kammesheidt - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Circulating tumor DNA(ctDNA) testing to detect identical gene mutation rates of KRAS, NRAS, PIK3CA and P53 compared to tissue-based testing and reflects treatment efficacy in patients with colorectal cancer.

Yanhong Deng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Filters

1321 Abstracts